MARIANNE ROSATI: Open Payments
NPI 1568445237 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,323 in 92 payments from 10 companies in 2025. Trend: 2023 $519 · 2024 $1,458 · 2025 $2,323
Food & beverage: $2,323
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 28 | $1,080 |
| Gilead Sciences, Inc. | 18 | $354 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $233 |
| Intercept Pharmaceuticals, Inc. | 5 | $214 |
| Ipsen Biopharmaceuticals, Inc | 9 | $209 |
| ABBVIE INC. | 5 | $91 |
| AstraZeneca Pharmaceuticals LP | 2 | $62 |
| ORPHALAN INC | 2 | $41 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| Eton Pharmaceuticals, Inc. | 1 | $16 |
Products named: REZDIFFRA, XIFAXAN, OCALIVA, IQIRVO, MAVYRET, CUVRIOR, Livmarli, GALZIN.
Industry payments across AZ — which companies pay providers there.
